Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
PLX
#3115
Protalix BioTherapeutics, Inc. Common Stock
2.830
0
USD
+1.07%
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
+1.07%
Monthly Change
-3.08%
6 month change
-3.08%
Year Change
-3.08%
Previous Close
2.800
0
Open
2.820
0
Bid
2.830
0
Ask
2.833
0
Low
2.789
0
High
2.845
0
Volume
288
Markets
US Stock Market
Healthcare
PLX
Open full chart
Financials
Overview
Statement
Statistics
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Key stats
Total common shares outstanding
73.63 M
78.03 M
79.61 M
79.73 M
80.42 M
—
Valuation ratios
Enterprise value
47.7 M
126.94 M
184.34 M
100.11 M
164.89 M
576.27 M
Price to earnings ratio
-8.5
47
51.2
16.44
27.75
142.39
Price to sales ratio
1.68
2.85
3.26
1.84
2.82
10.78
Price to cash flow ratio
50.02
17.57
21
6.2
9.64
54.4
Price to book ratio
0.62
3.53
1.31
0.67
0.91
6.41
Enterprise value to EBITDA ratio
-6.31
-36.71
56.42
14.49
32.39
66.6
Profitability ratios
Return on assets %
-0.05
-0.01
0.05
-0
-0.03
0.01
Return on equity %
-0.1
-0.01
0.08
-0
-0.04
0.02
Return on invested capital %
-62.76
1.73
39.94
-15.1
-15.89
10.67
Gross margin %
53.37
78.67
19.11
62.51
53.37
213.66
Operating margin %
-22.22
3.43
40.99
-7.48
-11.94
24.99
EBITDA margin %
24.05
41.4
-64.16
9.78
14.02
1.05
Net margin %
-18.02
-3.46
35.79
-1.05
-13.19
18.09
Liquidity ratios
Quick ratio
1.27
1.52
1.69
1.84
2.06
7.1
Current ratio
1.98
2.34
2.49
2.72
3.03
10.58
Inventory turnover
—
—
—
—
—
—
Asset turnover
0.23
0.27
0.14
0.21
0.22
0.83
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
0
—
—
—
—
Long term debt to total equity ratio
—
0
—
—
—
—
Per share metrics
Operating cash flow per share
0.06
0.05
0.07
0.07
0.05
0.23
EBIT per share
0.05
0.09
-0.09
0.02
0.03
0.04
EBITDA per share
0.06
0.09
-0.08
0.02
0.03
0.06
Total debt per share
—
—
—
—
—
—
Cash per share
0.37
0.24
0.25
0.23
0.17
0.9
Net current asset value per share
0.65
0.74
0.79
0.84
0.85
3.22
Tangible book value per share
0.44
0.53
0.59
0.64
0.68
2.44
Working capital per share
0.32
0.43
0.47
0.53
0.57
2
Book value per share
0.44
0.53
0.59
0.64
0.68
2.44
Protalix BioTherapeutics Inc (DE)
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
News
Brazil judge overrules decisions suspending changes to meal voucher system
A March Decision That Could Change Protalix’s Outlook (NYSE:PLX)
Pluxee, Edenred shares jump after upbeat results and outlook
Pluxee posts 9% growth in Q1; confirms 2026 outlook despite Brazil headwinds
Tuesday’s Insider Activity: Key Execs Make Notable Trades
BioMarin: Amicus Buyout Sparks My Enthusiasm (NASDAQ:BMRN)
Protalix and Secarna partner to develop rare kidney disease treatments
Pluxee revises fiscal 2026 outlook following Brazil regulatory changes
Deutsche Bank cuts Pluxee to “hold” after Brazil issues new voucher rules
Protalix BioTherapeutics, Inc. (PLX) Q3 2025 Earnings Call Transcript
Protalix earnings missed by $0.04, revenue fell short of estimates
Disney, Brookfield, Nu Holdings and more set to report earnings Thursday